(Q41475312)

1 October 2017

title

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis (English)

1 reference

1 October 2017

0 references

1 reference

14

1 reference

1 October 2017

13

Dick van Soolingen

1 reference

1 October 2017

Sunita Rehal

12

0 references

Norbert Heinrich

object named as

Norbert Heinrich

11

0 references

Stephen H Gillespie

object named as

Stephen H Gillespie

8

0 references

Michael Hoelscher

10

object named as

Michael Hoelscher

1 reference

1 October 2017

1

Martin J Boeree

1 reference

1 October 2017

15

Cecile Magis-Escurra

1 reference

1 October 2017

18

Rob E Aarnoutse

1 reference

1 October 2017

Andreas H Diacon

2

1 reference

1 October 2017

Rodney Dawson

3

1 reference

1 October 2017

Kim Narunsky

4

1 reference

1 October 2017

Jeannine du Bois

5

1 reference

1 October 2017

Amour Venter

6

1 reference

1 October 2017

Patrick P J Phillips

7

1 reference

1 October 2017

Timothy D McHugh

9

1 reference

1 October 2017

David Burger

16

1 reference

1 October 2017

Georgette Plemper van Balen

17

1 reference

1 October 2017

PanACEA Consortium

19

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

1 October 2017

published in

1 reference

1 October 2017

volume

191

1 reference

1 October 2017

issue

9

1 reference

1 October 2017

page(s)

1058-1065

1 reference

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Idiosyncratic drug reactions: the reactive metabolite syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Legionnaires' disease. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Prosthetic-joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Clinical Pharmacokinetics of Rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Early bactericidal activity of antituberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201407-1264OC

10.1164/RCCM.201407-1264OC

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference